COGNITIVE & NOOTROPIC RESEARCH / FAQ
Questions About DSIP and Semax
Direct, citation-anchored answers to the questions people most often bring to these two peptides.
What is DSIP peptide?
DSIP (Delta Sleep-Inducing Peptide) is a small, naturally occurring nonapeptide first isolated from the blood of rabbits during electrically induced sleep. It is not an FDA-approved medicine anywhere; it is sold only as an unregulated research chemical. Despite forty-plus years of study, no DSIP receptor, gene, or precursor has ever been identified, and a widely cited 2006 review described the sleep-inducing evidence behind it as "extremely poorly documented and still weak" [2].
What is DSIP peptide used for?
In research settings, DSIP has been studied for sleep architecture, the body's stress (HPA-axis) hormone signaling, and, in one Russian research lineage, lifespan and tumor-incidence outcomes in mice [3]. In humans, small 1980s studies looked at its effects on plasma ACTH levels [4] and on sleep quality in people with chronic insomnia [5]. None of this constitutes an approved medical use, and no dose is recommended on this site.
What are the benefits of DSIP peptide?
In a controlled human study, intravenous DSIP improved several measures of disturbed sleep — longer duration, fewer interruptions, slightly more REM sleep, and no daytime sedation — in a small group of chronic insomniacs [5]. In community reports (anecdotal, not clinical evidence), people describe an easier transition into sleep, deeper and more restorative-feeling sleep, and waking up without the grogginess associated with melatonin. A large share of users, however, report no noticeable benefit at all, so treating DSIP as a reliable sleep aid is not supported by the evidence.
Does DSIP really work?
The honest answer is: sometimes, in some contexts, inconsistently. A small 1981 human trial found genuine sleep-quality improvements [5], and a 2024 engineered fusion version of DSIP performed well in an animal insomnia model [1] — but the underlying native peptide's sleep evidence has been directly criticized in the scientific literature as weak and poorly documented [2], and a commonly repeated community estimate is that DSIP works meaningfully for only about half of the people who try it.
What is Semax?
Semax is a synthetic heptapeptide built from a fragment of adrenocorticotropic hormone (ACTH) with an added tail that slows its breakdown in the body. It lacks ACTH's cortisol-releasing effect. In animal research, it reliably raises the neurotrophins BDNF and NGF in specific brain regions [8][9] and is registered as a prescription drug in Russia and Ukraine for conditions including stroke and cognitive impairment. It is not FDA- or EMA-approved.
What is Semax peptide used for?
Semax has been studied for cognition and memory, mood and stress resilience, and neuroprotection after brain and spinal-cord injury. Research findings include improved functional recovery after spinal-cord injury in mice [6], reduced infarct size and preserved memory in a rat ischemia model [10], and immune- and vascular-gene changes underlying its protective effect after stroke in rats [7]. In Russia and Ukraine it is a registered clinical treatment for some of these conditions; elsewhere it is a research chemical only.
Is Semax a peptide?
Yes. Semax is a synthetic linear heptapeptide (H-Met-Glu-His-Phe-Pro-Gly-Pro-OH, or MEHFPGP), built from the natural ACTH(4-7) fragment with an added Pro-Gly-Pro tail attached to slow enzymatic breakdown. It is commonly supplied as the acetate salt and is most often studied and used via intranasal administration [11].
How does Semax work?
Semax's best-characterized action is raising two brain growth factors, BDNF and NGF, in specific regions within hours of dosing, via a specific and reversible binding site measured in rat brain tissue [8][9]. It also inhibits enzymes that break down the body's own opioid-like signaling peptides in laboratory testing [12], and in injury models its protective effect appears to involve broad shifts in immune- and vascular-related gene expression rather than a single mechanism [7].
What's the real difference between DSIP and Semax?
DSIP is oriented toward sleep and has no identified receptor after four decades of study, with inconsistent evidence and a large reported non-response rate [2]. Semax is oriented toward daytime focus, memory, and neuroprotection, and has a much more specific, measurable mechanism — a defined brain-binding site and a repeatable neurotrophin effect [9] — along with genuine (if geographically narrow) human clinical use in Russia and Ukraine. See the full comparison page for the side-by-side.
Are DSIP and Semax safe?
"Safe" is not a settled question for either. Both are sold only as unregulated research chemicals outside a narrow Russian/Ukrainian prescription niche for Semax, so purity and dosing accuracy are not guaranteed. DSIP's biggest safety honesty is that its mechanism is genuinely unknown, making interactions unpredictable [2]. Semax's biggest safety caution is that it can meaningfully potentiate stimulants and antidepressants through its effect on opioid-peptide-degrading enzymes [12], and its intranasal route commonly irritates the nasal lining [11]. Neither has been studied for pregnancy, breastfeeding, or long-term daily use in healthy people. This page describes cited findings; it is not a safety clearance for any individual, which requires a licensed clinician.